ArticleFrontiers in medicine2026
Development and internal validation of a prognostic nomogram for recurrence in chronic rhinosinusitis with nasal polyps after functional endoscopic sinus surgery.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently recurs after functional endoscopic sinus surgery (FESS). This study aimed to develop and internally validate a prognostic nomogram for predicting the two-year recurrence-free rate (RFR) in patients with CRSwNP after FESS. Methods: A total of 404 patients with CRSwNP who underwent FESS were retrospectively enrolled and randomly divided into a training cohort (n = 303) and an internal validation cohort (n = 101). Recurrence was defined as the first postoperative detection of nasal polyps by nasal endoscopy within 2 years. Candidate predictors were selected using LASSO Cox regression and further evaluated using multivariate Cox regression. A nomogram was constructed to predict the two-year RFR. Results: During the two-year follow-up, 148 patients experienced recurrence. Five independent predictors were included in the final model: number of previous nasal surgeries, olfactory cleft polyp, Lund-Mackay score, peripheral blood eosinophil percentage, and tissue eosinophil percentage. The nomogram showed good discrimination, with C-indices of 0.751 (95% CI, 0.707-0.795) in the training cohort and 0.707 (95% CI, 0.625-0.789) in the internal validation cohort. Calibration curves demonstrated good agreement between predicted and observed two-year RFR. Risk stratification based on the nomogram score separated patients into low-, intermediate-, and high-risk groups with significantly different RFRs. Conclusion: We developed and internally validated a nomogram for estimating two-year recurrence-free rate in patients with CRSwNP after FESS. The nomogram will help identify patients at high risk of recurrence and assist in the development of individualized treatment plans for patients with CRSwNP. Furthermore, we found that olfactory cleft polyps were a new independent risk factor for the postoperative recurrence of CRSwNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.